Strengths Acts via multiple pathways (GLP-1, AMPK, microbiome) Has existing human data showing reductions in fasting glucose, HbA1c, lipids Support receptor expression and islet health Limitations Low absorption and bioavailability Gastrointestinal discomfort is common (diarrhea, cramping)
Simultaneously, we proved the bio-distribution and AML cell retaining ability were greatly ameliorated in vivo, paving the road to clinical development of oridonin for AML therapy
Global status report on the public health response to dementia: executive summary
These changes can result in slower information processing, reduced motor coordination, and increased cognitive inflexibility (Yang et al., 2018)
Saito, C., Zwingmann, C
The depot effect in adipose tissue extends GHK-Cu half-life by 4060% compared to IM bolus, reducing required injection frequency from daily to every 34 days